General MedicationsINJECTIONStandard
ADAKVEO
CRIZANLIZUMAB-TMCA
Standard Dose
100MG/10ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ADAKVEO is listed in Drugs@FDA under application 761128 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient CRIZANLIZUMAB-TMCA Form and strength INJECTABLE; INJECTION - 100MG/10ML Sponsor NOVARTIS PHARMS CORP Submission history Latest submission status date: 2024-06-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview ADAKVEO is listed in Drugs@FDA under application 761128 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient CRIZANLIZUMAB-TMCA Form and strength INJECTABLE; INJECTION - 100MG/10ML Sponsor NOVARTIS PHARMS CORP Submission history Latest submission status date: 2024-06-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.